ALT Altimmune Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALT

Price (delayed)

$3.19

Market cap

$620.51M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.77

Enterprise value

$592.2M

?
Relative Growth: Rel. Growth: 40
Relative Strength: Rel. Strength: 39
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 33

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH.

Highlights
The equity has surged by 194% year-on-year and by 67% since the previous quarter
Altimmune's EPS has increased by 35% YoY and by 16% QoQ
The gross profit has soared by 107% YoY but it has contracted by 14% from the previous quarter
ALT's revenue has surged by 107% year-on-year but it is down by 14% since the previous quarter
The debt has surged by 142% year-on-year
Altimmune's net income has decreased by 4.6% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://altimmune.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ALT

ALT stock price

How has the Altimmune stock price performed over time
Intraday
-6.45%
1 week
-1.54%
1 month
2.57%
1 year
-15.83%
YTD
-11.63%
QTD
4.93%

Financial performance

How have Altimmune's revenue and profit performed over time
Revenue
$31,000
Gross profit
$31,000
Operating income
-$100.23M
Net income
-$91.76M
Gross margin
100%
Net margin
-296,000%
The gross profit has soared by 107% YoY but it has contracted by 14% from the previous quarter
ALT's revenue has surged by 107% year-on-year but it is down by 14% since the previous quarter
The net margin has increased by 49% year-on-year but it has declined by 17% since the previous quarter
The operating margin is up by 49% year-on-year but it has declined by 20% since the previous quarter

Price vs fundamentals

How does ALT's price correlate with its fundamentals

Growth

What is Altimmune's growth rate over time

Valuation

What is Altimmune stock price valuation
P/E
N/A
P/B
1.31
P/S
19,082.76
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
19,103.34
Altimmune's EPS has increased by 35% YoY and by 16% QoQ
The equity has surged by 194% year-on-year and by 67% since the previous quarter
The P/B is 42% lower than the 5-year quarterly average of 2.4 and 7% lower than the last 4 quarters average of 1.5
ALT's P/S is 138% above its 5-year quarterly average of 8567.7 and 38% above its last 4 quarters average of 14766.3
ALT's revenue has surged by 107% year-on-year but it is down by 14% since the previous quarter

Efficiency

How efficient is Altimmune business performance
The company's return on invested capital has surged by 73% YoY and by 41% QoQ
Altimmune's return on sales has surged by 52% YoY but it has decreased by 16% QoQ
ALT's ROA has soared by 51% YoY and by 24% QoQ
The return on equity rose by 50% year-on-year and by 26% since the previous quarter

Dividends

What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Altimmune financials performed over time
The total assets has soared by 177% YoY and by 57% from the previous quarter
The total liabilities has soared by 83% year-on-year and by 2.6% since the previous quarter
The debt is 93% smaller than the equity
The equity has surged by 194% year-on-year and by 67% since the previous quarter
The debt has surged by 142% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.